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and the Lung Cancer Disease Site Group of Cancer Care Ontario’s Program in Evidence-based Care§
Purpose: To conduct a systematic review to determine the most
effective therapy for patients with unresected stage III non-small cell
lung cancer.
Methods: Relevant randomized trials and meta-analyses were iden-
tified through a systematic search of the literature.
Results: Forty-seven trials and six meta-analyses were included. No
statistically significant survival differences were detected for imme-
diate versus delayed administration of radiotherapy or different
doses of hyperfractionated radiotherapy. Three of 12 trials compar-
ing various doses and schedules of radiotherapy detected a statisti-
cally significant survival advantage with higher radiation doses. All
meta-analyses found a statistically significant survival advantage for
chemoradiation, particularly platinum-based, compared with radia-
tion alone. One meta-analysis and three trials comparing concurrent
with sequential chemoradiation detected a statistically significant
survival advantage with concurrent administration. Increased toxic-
ities, especially esophagitis and hematologic events, were generally
associated with concurrent chemoradiation. The survival advantage
for concurrent platinum-based chemoradiation corresponds to a 4%
absolute survival benefit at 2 years. With respect to trials comparing
different chemotherapy regimens or schedules, there is insufficient
evidence to determine which particular regimen or schedule is most
effective.
Conclusion: Palliative radiotherapy can provide symptom relief for
symptomatic patients with poor performance status. For patients
with good performance status, chemoradiation improves survival
compared with radiotherapy alone, particularly when the two mo-
dalities are administered concurrently. Sequential chemoradiation is
a treatment option for borderline-status patients. Adequate assess-
ment of performance status is important when evaluating treatment
options for patients with unresected non-small cell lung cancer.
Patients and physicians should have a full discussion of the benefits,
limitations, and toxicities of therapy.
Key Words: Non-small cell lung cancer, Unresected stage III,
Radiation, Chemoradiation.
(J Thorac Oncol. 2006;1: 377–393)
Globally, lung cancer is the leading cause of cancer deathin men and the second leading cause in women.1 Non-
small cell lung cancer (NSCLC) accounts for 75% to 80% of
lung cancer cases, and most of these cases will be locally
advanced (stage III) or metastatic (stage IV) at the time of
presentation.2 The 5-year survival for patients with locally
advanced disease is approximately 15% for stage IIIA and
5% for stage IIIB when the Tumor Nodes Metastases (TNM)
staging system developed by Mountain was applied to a large
database.3 Until recently, the generally accepted standard
therapy for patients with locally advanced, unresectable
NSCLC was radiation therapy.2
Radiotherapy commonly relieves the symptoms of lo-
cally advanced NSCLC, and there is a small percentage
(approximately 5%) of long-term survivors after radical ra-
diotherapy. Attempts to improve survival with high-dose
radiotherapy have been reported in numerous studies. How-
ever, controversy remains as to whether radiotherapy should
be immediate or delayed, and uncertainty remains as to what
the total radiotherapy dose should be. Until 1990, randomized
controlled trials had not demonstrated a survival benefit for
patients who received immediate radiotherapy alone, deliv-
ered with modern megavoltage equipment, compared with
patients who were given radiotherapy only when they became
symptomatic.
The use of systemic treatment in combination with
radiation (chemoradiation) has been investigated because of
evidence of tumor regression and a small survival benefit
with chemotherapy in metastatic NSCLC. A large meta-
analysis published in 1995 demonstrated a survival benefit for
patients treated with chemoradiation (combined modality
therapy) compared with radiotherapy alone4; however, the
results of individual studies have been conflicting. The ad-
ministration of chemotherapy and radiotherapy within a che-
moradiation regimen may be sequential (one modality is
followed by the other modality) or concurrent (the two
modalities are administered at the same time). In addition,
chemoradiation may be preceded by a course of chemother-
apy (induction therapy) or followed by a course of chemo-
therapy (consolidation therapy). The relative effectiveness of
*Juravinski Cancer Centre at Hamilton Health Sciences and McMaster
University, Hamilton; †Cancer Care Ontario Program in Evidence-based
Care, McMaster University, Hamilton; ‡Toronto-Sunnybrook Regional
Cancer Centre, Toronto, Ontario, Canada; §See the Program in Evi-
dence-Based Care section of Cancer Care Ontario’s Web site for a list of
current Disease Site Group members (http://www.cancercare.on.ca/).
Address for correspondence: Ms. Jean Mackay, Cancer Care Ontario Pro-
gram in Evidence-based Care, McMaster University Downtown Campus,
1280 Main St. W, Hamilton, ON, Canada L8S 4L8. E-mail: vanderja@
mcmaster.ca
Copyright © 2006 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/06/0104-0377
Journal of Thoracic Oncology • Volume 1, Number 4, May 2006 377
different chemoradiation regimens and schedules remains
undefined. We conducted this systematic review to evaluate
the most effective therapy for unresected stage III NSCLC.
The following questions were investigated: 1) What is the
role of radiotherapy as a treatment in patients with unresected
stage III NSCLC, and what are the preferred schedules or
doses of radiotherapy administration? 2) Does chemotherapy
combined with radiotherapy improve survival compared with
radiotherapy alone in patients with unresected stage III
NSCLC? 3) Which sequence of radiotherapy combined with
chemotherapy is most effective in improving survival for
patients with unresected stage III NSCLC? 4) Which chemo-
therapy regimen, combined with radiotherapy, is most effec-
tive in improving survival for patients with unresected stage
III NSCLC?
METHODS
This systematic review was developed by Cancer Care
Ontario’s (CCO) Program in Evidence-based Care and forms
the basis for a practice guideline. Evidence was selected and
reviewed by two members of the Lung Cancer Disease Site
Group (Lung DSG). Practice guidelines developed through
the Program follow the methods of the Practice Guidelines
Development Cycle5 and are available on the Program in
Evidence-based Care section of the CCO Web site at http://
www.cancercare.on.ca/. This review has been edited and
condensed for publication, but the unabridged version is
available on the CCO Website.
Literature Search Strategy
Literature searches were conducted on MEDLlNE
(1966 through November 2005), EMBASE (1980 through
2005, week 46), and the Cochrane Library (2005, Issue 4).
Search terms included subject headings (carcinoma, non-
small cell lung; lung carcinogenesis; lung adenocarcinoma;
lung alveolus cell carcinoma; lung, non-small cell cancer;
lung squamous cell carcinoma; radiotherapy; cancer radio-
therapy), text words (non-small cell lung, radiotherapy, radi-
ation therapy, chemoradiation, inoperable, unresectable), and
publication types and study designs (practice guidelines,
systematic reviews or meta-analyses, randomized controlled
trials, and controlled clinical trials). Abstract reports from the
American Society of Clinical Oncology (ASCO, 1999-2005)
and the American Society for Therapeutic Radiology and
Oncology (ASTRO, 1999-2004) and reference lists from
relevant articles and reviews were hand searched. The Cana-
dian Medical Association Infobase (http://mdm.ca/cpgsnew/
cpgs/index.asp) and the National Guidelines Clearinghouse
(http://www.guideline.gov/index.asp) were also searched for
existing, evidence-based practice guidelines published since
2000.
Study Selection Criteria
Articles were included in this systematic review if they
were fully published reports or abstracts of meta-analyses or
randomized trials (phase II or III) comparing the following
approaches in patients with unresectable stage III NSCLC: 1)
Different schedules or doses of radiotherapy as a single
modality treatment; 2) Radiotherapy alone versus the same
radiotherapy regimen combined with chemotherapy; 3) Dif-
ferent chemoradiation regimens that differ only in the radia-
tion regimen used; 4) Different chemoradiation regimens that
differ only in the chemotherapy regimen used; or 5) Timing
of radiotherapy and chemotherapy administration within a
chemoradiation treatment approach.
In addition, evidence-based practice guidelines or sys-
tematic reviews that addressed radiotherapy-based treatment
for unresectable stage III NSCLC and included recommen-
dations published since 2000 were eligible. Trials evaluating
any of the following treatment options or comparisons were
not eligible: older radiotherapy equipment (e.g., equipment
that antedated Cobalt-60), three-dimensional conformal ra-
diotherapy, bronchial artery infusion chemotherapy, split-
course radiotherapy compared with another radiotherapy
schedule, or conventional compared with altered fraction-
ation radiotherapy (for guidelines on altered fractionation
radiation therapy in the management of unresectable NSCLC,
visit the CCO Website at http://www.cancercare.on.ca/). Tri-
als of chemoradiation involving a non-platinum chemother-
apy combination and published before 1995 were excluded as
meta-analyses have shown a survival advantage for chemo-
radiation over radiation alone only for platinum-based che-
motherapy and not other chemotherapies.4,6 In addition, trials
that randomized only patients who had responded to, or did
not progress on, induction chemotherapy, or did not report the
required outcomes by treatment group were not considered.
For trials examining treatments with palliative intent, the
required outcomes included symptom control or quality of
life (QOL); for all other trials, survival data were required.
Trials published in a language other than English were
excluded.
RESULTS
Literature Search Results
Forty-seven randomized trials (phase II and phase III)
and six meta-analyses met the eligibility criteria for this
systematic review. Of those, 46 were fully published reports,
and seven were in abstract or brief report form only. Data
from slide presentations associated with abstract trial reports
were also included if the presentations were publicly avail-
able on meeting Websites. In addition, five relevant evidence-
based practice guidelines and systematic reviews were iden-
tified.7–11 Randomized trials of conventional radiotherapy
that were included in published meta-analyses of chemora-
diation versus radiation alone are not reported separately in
this guideline report, with the exception of trials involving
chemotherapy used as a radiosensitizer. Those were included
because none of the meta-analyses examined this form of
treatment administration separately.
Practice Guidelines and Systematic Reviews
During the development of this review, three evidence-
based guidelines on treatment for NSCLC and two systematic
reviews that included guidance on the use of radiotherapy in
NSCLC were published.7–11 The focus of each report differed
to some extent, although the relevant recommendations and
guidance from the documents are generally consistent. In
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particular, the reports agree that combined platinum-based
chemoradiation is the appropriate treatment for patients with
unresectable locally advanced NSCLC of good performance
status (PS).8–11 Most of the reports also agree that palliative
radiotherapy alone can provide symptom relief in selected
patients with symptomatic, unresectable NSCLC.7,8,11 There
is considerable overlap in the studies reviewed in each of
those guidelines and systematic reviews; however, the Lung
DSG identified additional studies, including recent publica-
tions, which were relevant to the current topic. In addition,
the Lung DSG believed that a separate review of some
treatment approaches would be of value (e.g., low-dose
chemotherapy used as a radiosensitizer within a combined
modality treatment regimen).
Outcomes
None of the trials included in this review reported
blinding of treatment administration for patients or trial
clinicians. Blinding can limit measurement bias, particularly
for the subjective outcomes used in palliative radiotherapy
trials, such as QOL and symptom control.12 Missing data are
also of concern with QOL assessments,13 and few trials
discuss how this issue is addressed. These factors should be
taken into account when considering the results of subjective
outcome assessments. Results from randomized phase III
trials are the focus of this review. Randomized phase II trials
are generally designed to assess the efficacy of individual
treatments rather than to compare effectiveness among treat-
ments, and abstract trial reports provide limited methodolog-
ical detail on which to evaluate trial quality. However, data
from randomized phase II trials and abstract trial reports are
included in the review tables because they provide data on
treatment toxicities and supporting data for the comparative
randomized trials.
Radiotherapy Alone
Fifteen randomized trials addressed the role of radio-
therapy alone (Table 1). Two trials were reported in abstract
form and provided limited methodological detail.14,15 A qual-
ity assessment of trials revealed that, of the 13 fully published
trials, all but two16,17 were conducted among multiple sites.
Randomization was centralized in most trials and conducted
by telephone, although three trials used a sealed envelope
system16–18 and three trials did not report the method of
randomization.19–22 Seven trials described how the required
sample size was determined,16,18–21,23–25 including one trial
designed as an equivalence trial,20 with four failing to reach
the specified target.18,21,23,25 Of the trials reporting survival
data, only one included fewer than 96% of randomized
patients in the survival analysis,26 although two trials did not
clearly report the number of patients included in the analy-
ses.17,18 Two trials specified that linear accelerators were used
to deliver radiotherapy,17,19 most described treatment as pal-
liative 16–21,23–25,27,28, and two included survival as the pri-
mary outcome of interest.18,24 Only two trials reported good
PS (0-2) as an inclusion criteria.18,24
Immediate Versus Delayed Radiotherapy
Two randomized trials, including one reported in ab-
stract form, compared immediate treatment with radiotherapy
versus treatment delayed until symptom control became nec-
essary.14,23 In the trial by Falk et al.,23 radiotherapy was
administered to 90% of patients assigned to immediate treat-
ment and 42% assigned to delayed treatment. Neither trial
detected a statistically significant survival difference between
treatments, although this was a secondary outcome in the
fully published trial,23 and the results in the abstract report
were based on preliminary data.14
Variable Doses and Schedules of Conventional
Radiotherapy
Twelve trials, including one reported in abstract form,
compared different doses or schedules of radiation adminis-
tered in a conventional manner.15–21,24–28 Radiation in a dose
of 17 Gy in two fractions over 1 week was the most fre-
quently examined schedule.16,24,25,27,28 Treatment in most
trials was described as palliative or could be inferred as
palliative from the radiotherapy dose and schedule used,
except for one trial in which the treatment was described as
radical.26 The definition of a palliative dose varies, and in
Canada, doses higher than 30 Gy would generally be consid-
ered radical in nature. Therefore, treatment in some of the
trials17,18,24,25 would be considered radical in Canada, despite
the stated palliative intent. Limitations in the conduct of four
trials were noted. In the trial by Teo et al.,17 there was an
imbalance in the number of patients allocated to each treat-
ment. Eighteen patients (6%) were also excluded from anal-
yses because they did not complete treatment, and 36 patients
(12%) were not evaluable for symptom improvement. Two of
the five centers in the trial by Sundstrøm et al.25 refused to
enroll patients in the 50 Gy treatment arm in the last year of
the study because of an inadequate capacity for radiotherapy,
which resulted in a lower patient accrual in that treatment
arm. The primary outcome measure in the trial by Kramer et
al.20 was based on an unvalidated adaptation of the Rotterdam
Symptom Checklist, and the Polish trial closed prematurely
because of decreasing accrual after enrolling only 100 of the
planned 321 patients.21
Only four of the 12 trials detected a statistically signif-
icant survival difference between radiotherapy schedules. In
three of those trials, longer survival was associated with
higher doses of radiotherapy delivered more frequently; how-
ever, no single dose or schedule was consistently superi-
or.19,20,24 The reliability of the results in the fourth trial was
limited because survival was a secondary outcome and ac-
crual was halted early.21 Among the four trials conducted in
the United Kingdom, only the trial that focused exclusively
on patients with a good to moderate PS (0-2) detected a
significant survival benefit with a higher dose multifraction
regimen, compared with the 17 Gy in two fractions over
1-week approach.24 Similarly, an exploratory subgroup analysis
of the multicenter Canadian trial by Bezjak et al.19 suggested that
the survival benefit associated with a multifraction regimen
compared with a single-fractionated regimen was specific to
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TABLE 1. Randomized trials of radiotherapy alone
Study Disease stage Radiotherapy regimen n
Response,
CR & PR
(%)
Survival
Symptom control
(% of patients)Median (mo) 1-year(%)
Immediate vs. delayed radiotherapy
Alberti et al.14 Limited Delayed
Immediate, 52-56 Gy
Immediate CTa followed
by 52-56 Gy
63
total
NA
78
76
11
15
19
NR NR
Falk et al.23 Locally
advanced/
metastasis
Delayed
Immediate, 17 Gy, 2 fx,
2 wks OR 10 Gy, 1 fx
115
115
NR 7.9
8.3
29
31
No statistical differences over 6 mo
(clinician or patientb assessed)
HR 0.95, 95% CI, 0.73-1.24,
p  0.71 log rank
Comparisons of different doses and schedules of conventional radiotherapy
Perez et al.26 III 20 Gy X 2, split-course
40 Gy, 20 fx, 4 wks
50 Gy, 25 fx, 5 wks
60 Gy, 30 fx, 6 wks
254c
115
103
46d
51
66
61
NR
2-yr:
10
11
19
19
NR
Teo et al.17 I-III (92%
stage III)
31.2 Gy, 4 fx, 4 wks
45 Gy, 18 fx, 4.5 wks
153
138
50 f
53 f
NR NR 54%
71%
p  0.0122
e
Bleehan et al.27 Advanced 17 Gy, 2 fx, 1 wk
30 Gy, 10 fx or 27 Gy,
6 fx, 2 wks
374
total
29
31
5.9
5.8
20
23
Symptom palliation generally
similar among treatments on
patient diary cards & clinician
reports
p  0.8 log rank
Bleehan et al.28 Advanced 10 Gy, 1 fx
17 Gy, 2 fx, 1 wk
118
117
NR 4.0
3.3
9
14
Except for dysphagia, symptom
palliation generally similar
among treatments on patient
diary cards & clinician reports
HR 1.02 95% CI, 0.81-1.29
Abratt et al.18 III 35 Gy, 10 fx, 3 wks
45 Gy, 15 fx, 4 wks
43
41
56
51
8.5
8.5
40
37
Clinician-assessed: 68%
76%
at 2 mo post-rad
Macbeth et al.24 Advanced, non-
metastatic
17 Gy, 2 fx, 1 wk
39 Gy, 13 fx, 3 wks
255
254
NR 7
9
31
36
Patient-reported symptom
palliationb at 2 mo generally
better with 17 Gy, particularly
energy levels (44% vs. 30%) and
sleep difficulties (67% vs. 48%)
HR 0.82 95% CI, 0.69-0.99,
p  0.03 Mantel-Cox
Rees et al.16 NR
7/216 with
SCLC
17 Gy, 2 fx, 1 wk
22.5 Gy, 5 fx, 1 wk
111
105
NR NR NR Tendency toward improvement
with 17 Gy (patient report) but
NS on any symptom
HR 1.27 95% CI, 0.57-1.75
Gaze et al.15 Advanced 10 Gy, 1 fx
30 Gy, 10 fx
148
total
NR 5.3
6.5
NR Physician-rated symptom palliation
better with 30 Gy at 1 & 3 mo
(p  0.001)p  0.197
Bezjak et al.19 III-IV 10 Gy, 1 fx
20 Gy, 5 fx
116
114
NR 4.2
6.0
NR 1-mo follow-up: Patient-reported
symptoms (p  0.1); Improved
QOLb with 20 Gy (p  0.05) -
symptoms, global QOL, normal
activities, and pain
p  0.0305 log rank
Sundstrøm et al.25 III-IV 17 Gy, 2 fx
42 Gy, 15 fx
50 Gy, 25 fx
146
145
130
NR 8.2
7.0
6.8
29
29
31
Primary symptoms up to 54 wksb:
dyspnea, cough, hemoptysis, p 
NS. No consistent differences on
other QOLb or clinician-
evaluated measures
p  0.83 log rank
Kramer et al.20 III-IV 16 Gy, 2 fx, 1 wk
30 Gy, 10 fx, 2-3 wks
149
148
NR NR
p  0.03
11
20
Average total symptom score
similar by treatment with (p 
0.299) and without (p  0.22)
adjustment for initial symptom
score
Senkus-Konefka
et al.21
Locally advanced/
metastatic
16 Gy, 2 fx
20 Gy, 5 fx
45
55
29g
22g
8.0
5.3
27
11
For 58 evaluable patients: group
differences NS on symptomatic
response up to 8 wksp  0.016 log rank
Comparisons of different doses and schedules of hyperfractionated radiotherapy
Cox et al.22 II-IV All BID:
60 Gy, 25 fx, 5 wks
64.8 Gy, 27 fx, 6 wks
69.6 Gy, 29 fx, 6 wks
74.4 Gy, 31 fx, 7 wks
79.2 Gy, 33 fx, 7 wks
884
total
NR
9.2
6.3
10.0
8.7
10.5
39
33
44
40
45
NR
Table footnote continues
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patients with locally advanced disease and good PS (Eastern
Cooperative Oncology Group [ECOG], 0-1).
Perez et al.26 found that local recurrence rates were
inversely related to the radiotherapy dose, with a rate of 35%
after 60 Gy, 42% after 50 Gy, and 51% after 40 Gy (p 
0.006). In contrast, two trials detected no significant differ-
ence among radiation doses on local control (hazard ratio
[HR], 0.86; 95% confidence interval [CI], 0.68–1.0924; p 
0.6425). In one trial, distant metastases occurred earlier
among patients receiving the lower-dose radiation (HR, 0.69;
95% CI, 0.55-0.86).24 Few statistically significant treatment
differences were reported for symptom palliation. Dysphagia
was a common treatment side effect.
Hyperfractionated Radiotherapy
Only one phase I/II trial is available to assess the role
of hyperfractionated radiotherapy in locally advanced lung
cancer. That trial was designed to examine toxicity and tumor
control among five different hyperfractionated radiotherapy
doses, and no statistically significant survival or toxicity
differences were detected.22 With acceptable acute and late
toxicities in the three initial treatment arms (60-69.6 Gy),
recruitment to the two lowest-dose treatment arms was
closed, and two higher-dose treatment arms were added (74.4
and 79.2 Gy). Tumor response was not assessed because of
the difficulty in differentiating tumor from radiation changes
in the adjacent lung post-radiation therapy.
Chemoradiation Versus Radiation Alone
Meta-Analyses
Six meta-analyses have compared radiotherapy alone
with radiotherapy combined with chemotherapy (Table
2).4,6,29–33 One meta-analysis also compared concurrent with
sequential chemoradiation32 and is discussed in Timing of
Radiotherapy Relative to Chemotherapy. In three of the
meta-analyses, all published in the mid-1990s, the chemo-
therapy was administered either sequentially or concurrently
with radiotherapy.4,6,29,30 In three recent meta-analyses, in-
cluding one published in abstract form, only trials of concur-
rent chemoradiotherapy were included.31–33 There was con-
siderable overlap in the trials included in the six meta-
analyses. Three trials originally reported in one meta-analysis
as unpublished or available in abstract form only were sub-
sequently published in full.34–36
The largest analysis, conducted by the Non-Small Cell
Lung Cancer Collaborative Group, was based on individual
patient data from 22 randomized trials (published and unpub-
lished). Those trials accrued patients with locally advanced
disease between January 1, 1965 and December 31, 1991 and
recruited between 48 and 353 patients per trial.4,29 The
overall pooled mortality HR was 0.90 (p  0.006), demon-
strating an absolute survival benefit of 3% at 2 years in favor
of chemoradiation. Among subgroup analyses conducted on
the basis of the chemotherapeutic agent used, only the cis-
platin-based regimens demonstrated a statistically significant
survival advantage compared with radiotherapy alone, and
that corresponded to a 4% absolute survival benefit at 2
years.29 However, the test for interaction was not significant
for the different chemotherapy categories, suggesting that the
results of the subgroup analyses should be viewed with
caution.
Three of the other four fully published meta-analyses
included only published data,6,30,31 and one included unpub-
lished data for two studies reported in abstract form.32 Results
from the two meta-analyses involving both sequential and
concurrent chemoradiation trials were consistent with those
of the Non-Small Cell Lung Cancer Collaborative Group
meta-analysis.6,30 The two fully published meta-analyses re-
stricted to concurrent chemoradiation trials included mainly
platinum-based chemotherapy regimens with considerable
overlap in the trials analyzed in each report.31,32
In both of those meta-analyses, concurrent chemoradia-
tion improved survival compared with radiotherapy alone at
2 years, although there was significant heterogeneity in treat-
ment effects among the trials in one of the analyses32 (Table
2). Both meta-analyses also reported similar results for the
subgroup of trials involving weekly chemotherapy adminis-
tration; however, the results were less consistent for trials
involving daily chemotherapy administration or chemother-
apy administered two to four times a week.
An unplanned, exploratory subgroup analysis in one
report suggests that the survival advantage of chemoradiation
compared with radiation alone was maintained with once-
daily radiation (10 trials; relative risk [RR], 0.92; 95% CI,
0.87-0.99; p 0.02) but not twice-daily radiation (four trials;
RR, 0.95; 95% CI, 0.81-1.11; p 0.5).32 The results reported
in abstract form for one meta-analysis of concurrent chemo-
radiation versus radiation alone33 are comparable with the
results obtained in the fully published meta-analyses.
Only two meta-analyses explored the potential toxicity
of treatment. Acute grade 3 or greater adverse effects were
examined in the published meta-analysis by Rakovitch et al.31
Esophagitis, neutropenia, and pneumonia were more fre-
quently associated with concurrent chemoradiation compared
with radiation alone. However, the difference was statistically
significant only for esophagitis (RR, 1.77; 95% CI, 1.27-2.48;
Table continued
BID, twice daily; CI, confidence interval; CR, complete response; CT, chemotherapy; fx, fraction(s); HR, hazard ratio; NR, not reported; NS, not statistically significant; PR, partial
response; QOL, qualify of life; SCLC, small cell lung cancer.
aInduction CT: vindesine 3 mg/m2 days 1 and 3 and cisplatin 80 mg/m2 day 2 every 4 weeks for three courses.
bAssessed using a standardized scale: Rotterdam Symptom Checklist23,24; Lung Cancer Symptom Scale19,25; European Organization for Research and Treatment of Cancer19. One
trial evaluated symptom control using an unvalidated adaptation of the Rotterdam Symptom Checklist20, and one trial developed their own four-point scale21.
cBoth RT 20 Gy X 2 and RT 40 Gy groups combined.
dComplete response rate for the split-course radiotherapy regimen was lower than that for the other regimens (p  0.02)
eMethod of symptom assessment was not clearly described.
f There were 98 patients who were non-evaluable for response between both treatment arms combined.
gThe intention-to-treat tumor response rate is reported in the Table. The rate reported in the article was based on 47 evaluable patients: 20 versus 16 Gy, 52% versus 54%; p  0.99.
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p  0.0008) and neutropenia (RR, 9.15; 95% CI, 4.16-20.12;
p  0.00001) and not for pneumonitis (RR, 1.36; 95% CI,
0.89-2.07; p  0.16). That finding was consistent with the
results of Rowell and O’Rourke,32 who reported a signifi-
cantly increased rate of acute esophagitis in patients receiving
chemoradiation (RR, 1.58; 95% CI, 1.19-2.09; p 0.001) but
no significant treatment-related differences for acute pneu-
monitis (RR, 1.19; 95% CI, 0.64-2.22; p  0.6).
Chemotherapy as a Radiosensitizer Versus
Conventional Radiotherapy Alone
When administered concurrently with radiotherapy,
chemotherapy may enhance the local effect of the radiother-
apy by sensitizing tumor cells to the radiation. Trials that
primarily aim to evaluate the use of chemotherapy as a
radiosensitizer, i.e., those that involve low-dose chemother-
apy agents administered on a daily or weekly basis concur-
rently with radiotherapy, are included in this section.
Seven fully published randomized trials explored the
role of low-dose platinum chemotherapy administered con-
currently with radiotherapy as a radiosensitizer37–43 (Table
3). Data from four of these trials37–40 were included in three
meta-analyses6,30,31; however the trials were not analyzed
separately as radiosensitizing studies. Five of the trials in-
volved multiple centers,38–40,42,43 and one trial reported using
a centralized randomization process.38 Four trials described
TABLE 2. Meta-analyses of radiotherapy alone vs. chemo-radiotherapy.
Reference Comparisons Studies (n) Patients (n) Survival ratio (95% CI)a
Absolute
survival
difference
Non-small Cell Lung
Cancer Collaborative
Group4 and Cochrane
Lung Cancer Group29
RT vs. RT  any CT 22 3,033 HR, 0.90
p  0.006
3% at 2 yrs
2% at 5 yrs
Subgroup analyses
RT vs. RT  cisplatin-based CT 11 1,780 HR, 0.87 (0.79-0.96)
p  0.005
4% at 2 yrs
2% at 5 yrs
RT vs. RT  long-term alkylating
CT
5 665 HR, 0.98 (0.83-1.16)
p  0.81
NR
RT vs. RT  vinca alkaloid CT or
etoposide
3 349 HR, 0.87 (0.70-1.09)
p  0.23
NR
RT vs. RT  other CT 3 239 HR, 0.98 (0.74-1.29)
p  0.88
NR
Marino et al.6 RT vs. RT  cisplatin-based CT 10 1,410 2 yr OR, 0.70 (0.5-0.9) NR
RT vs. RT  non-cisplatin-based
CT
4 477 2 yr OR, 0.82 (0.5-1.3) NR
Pritchard et al.30 RT vs. RT  any CT 14 2,589 2-yr RR, 0.87 (0.81-0.94) 1.7 mo,
median
Subgroup analyses
RT vs. RT  cisplatin-based CT 11 2,158 2 yr RR, 0.85 (0.79-0.92) 1.6 mo,
median
RT vs. RT  sequential CT 8 1,408 2 yr RR, 0.85 (0.77-0.95) 1.7 mo,
median
RT vs. RT  concurrent CT 6 1,181 2 yr RR, 0.89 (0.81-0.98) 1.7 mo,
median
Rakovitch et al.31 RT vs. RT  concurrent CT 10 1,802 2 yr RR, 0.92 (0.88-0.97)
p  0.002
NR
Subgroup analyses
RT vs. RT  weekly concurrent CT 6b 1,128 2 yr RR, 0.93 (0.87-0.99)
p  0.02
NR
RT vs. RT  daily concurrent CT 5b 788 2 yr RR, 0.92 (0.85-1.00)
p  0.05
NR
Rowell et al.32 RT vs. RT  concurrent CT 13 2,214 2 yr RR, 0.93 (0.88-0.98)
p  0.01
NR
Subgroup analyses
RT vs. RT  concurrent platinum-
based CT
11 1,945 2 yr RR, 0.93 (0.87-0.99)
p  0.02
NR
RT vs. RT  weekly concurrent CT 5b 896 2-yr RR, 0.91 (0.84-0.98)
p  0.01
NR
RT vs. RT  daily concurrent CT 5b 716 2 yr RR, 0.95 (0.85-1.08)
p  0.5
NR
RT vs. RT  concurrent CT
administered 2-4 times a week
5b 777 2 yr RR, 0.92 (0.83-1.02)
p  0.12
NR
Auperin et al.33 RT vs. RT  concurrent platinum-
based CT
9 1,764 RR, 0.89 (0.81-0.98)
p  0.02
4% at 2 yrs
2% at 5 yrs
CI, confidence interval; CT, chemotherapy; HR, hazard ratio; NR, not reported; OR, odds ratio; RR, risk ratio; RT, radiotherapy.
aRatios less than one indicate a survival benefit in favor of chemoradiation.
bSome trials are included in more than one comparison.
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how the required sample size was determined.40–43 One trial
was terminated after 46 of a planned 190 elderly (71 years)
patients were enrolled because of a high proportion of treat-
ment-related deaths and protocol deviations.43 Five trials
included at least 95% of randomized patients in survival
analyses,37–39,41,42 and one trial excluded 12% of patients
because of ineligibility or failure to receive treatment, al-
though the number excluded in each treatment group was
similar.40 All the trials included only patients with a good or
moderate PS (0-1,37,40 0-2,38,41–43 Karnofsky 50%39), and
two also required minimal weight loss of 10%42 or 5% in
the 3 months preceding diagnosis.40 Two trials used linear
accelerators to deliver radiotherapy to some39 or all pa-
tients.42
A significant overall survival advantage in favor of
chemoradiation was found in two38,41 of the seven trials.
After a minimal 22-month follow-up, Schaake-Koning et al.38
reported that survival was significantly improved when daily
cisplatin was added to radiotherapy, but no statistically sig-
nificant survival benefit was detected for weekly cisplatin
with radiotherapy compared with radiotherapy alone. In a
multivariate analysis by Cakir et al.,41 radiation alone and a
radiation dose 60 Gy were each associated with poorer
survival. No association was observed between survival and
patient age, PS, or disease stage. In both trials, the survival
benefit of chemoradiation may have been the result of an
improvement in local control.38,41 Schaake-Koning et al.38
observed longer local recurrence-free survival with radiother-
apy and daily chemotherapy (1 year, 59%; 2 years, 31%)
compared with radiotherapy alone (1 year, 41%; 2 years,
19%; p  0.003) or radiotherapy with weekly chemotherapy
(1 year, 42%; 2 years, 30%; p  0.17). Similarly, Cakir et
TABLE 3. Randomized trials of conventional radiation with versus without chemotherapy used as a radiosensitizer
Study
Disease
stage Treatment n
Response,
CR & PR
(%)
Survival
Median (mo) Rate (%)
Soresi et al.37 IIIA/B
RT: 50.4 Gy, 28 fx, 5.5 wks
RTCT: RT as above  concurrent cisplatin
15 mg/m2 wkly
50
45
50
64
p  0.2
Actuarial
11
16
p  0.18 log rank
NR
Schaake-
Koning et
al.38
I-III
RT: 30 Gy, 10 fx  25 Gy, 10 fx, split-
course, 5 wks
RTCT: RT as above  concurrent cisplatin
30 mg/m2 wkly
RTCT: RT as above  concurrent cisplatin
6 mg/m2 daily
114
110
107
54
54
63
NR
Estimated
2-yr/3-yr
13/2
19/13
26/16
p  0.054 log rank, overall; p  0.36 log rank,
RT vs. RTCT wkly; p  0.009 log rank, RT
vs. RTCT daily
Trovo´ et al.39 IIIA/B RT: 45 Gy, 15 fx, 3 wks
RTCT: RT as above  concurrent cisplatin
6 mg/m2 daily
88
85
59
51
p  NS
10.3
9.97
p  NS
NR
Clamon et
al.40
IIIA/B
CT-RT: Induction vinblastine 5 mg/m2
wkly days 1-29  cisplatin 100 mg/m2
days 1 & 29 - 60 Gy, 30 fx, 6 wks
CT-RTCT: Induction CT - RT as
above  carboplatin 100 mg/m2 wkly
concurrent with RT
137
146
58
58
13.5
13.4
p  0.7426 log rank
2-yr/4-yr
26/10
29/13
Cakir et al.41 IIIA/B
RT: 64 Gy, 32 fx, 6.5 wks
RTCT: RT as above  concurrent cisplatin
20 mg/m2 days 1-5, wks 2 and 6
93a
92a
45b
64b
NR
p  0.00001 log rank
Estimated 3-yr
2
10
Groen et al.42 IIIA/B
RT: 60 Gy, 30 fx, 6 wks
RTCT: RT as above  concurrent,
continuous infusion carboplatin,
840 mg/m2, given over 6 wks
78
82
c 11.7 (95% CI, 8.1-15.5)
11.8 (95% CI, 9.3-14.2)
p  0.39 log rank
2-yr
28
20
Atagi et al.43 d IIIA/B
RT: 60 Gy, 30 fx, 6 wks
RT  CT: RT as above  concurrent
carboplatin 30 mg/m2 for first 20 fx
23
23
52
48
14.1
18.2
1-yr
60.9
65.2
CI, confidence interval; CR, complete response; CT, chemotherapy; fx, fraction(s); NR, not reported; NS, not statistically significant; PR, partial response; RT, radiotherapy.
aThere were 88 eligible in each group.
bReported as a statistically significant, but no p value was given.
cResponse data reported are inconsistent and range from 37% to 58%.
d Included patients 71 years old and was terminated after 46 patients because of a high proportion of treatment-related deaths and protocol deviations.
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al.41 detected higher rates of loco-regional recurrence after
radiotherapy alone (80% versus 60% of patients; p 0.0001)
but lower rates of distant recurrence (7% versus 24%; p 
0.07). In addition, two other trials observed higher rates of
local recurrence with radiation alone (46% versus 27%37;
53% versus 43%40), although distant recurrence rates were
higher with chemoradiation in one trial (40% versus 28%40)
and similar among treatments in the other trial (29% to
32%37). Two trials did not observe a difference in relapse
patterns between chemoradiation and radiation alone.39,42 Of
the trials that did not detect a significant survival difference
between treatments, two involved concurrent carboplatin ad-
ministration,40,42 one reported a minimal follow-up period
that was shorter than the median survival time,39 one only
included patients 71 years old and was stopped early
because of treatment-related deaths and protocol deviations,43
and one was likely underpowered to detect a survival differ-
ence.37
Non-hematologic toxicities were generally comparable
among treatments, although patients who underwent chemo-
radiation experienced more nausea and vomiting in two trials
(grade 3 or 4, 25% to 28% versus 2%;38 any grade, 29%
versus 10%39) and more bacterial pneumonitis in one trial
(11% versus 4%).37 Two trials observed increased grade 3 or
4 esophagitis when cisplatin (16% versus 8%39) or carbopla-
tin (9% versus 2%42) was added to radiotherapy. Higher rates
of grade 3 or 4 hematologic toxicity were associated with
chemoradiation compared with radiotherapy alone in two
trials (14% to 59% versus 2% to 44%40; 11% versus 0%42).
Schaake-Koning et al.38 reported two possible treatment-
related deaths, both in the weekly chemotherapy treatment
group. Atagi et al.43 reported four treatment-related deaths,
three in the chemoradiation arm and one in the radiation arm.
In the one trial that assessed patient QOL, using the
European Organization for Research and Treatment of Can-
cer (EORTC) scales, no statistically significant differences
were detected for the 72% of patients who provided data 3
months post-treatment.42
Chemoradiation Versus Conventional Radiation
Alone
Seven trials compared chemoradiation with radiation
alone but were not included in any of the meta-analyses
(Table 4).44–50 Two trials were randomized phase II trials,44,50
three trials involved multiple centers,45–47 two used a central-
ized randomization process,45,46 and four described the
method of sample size estimation.45,46,49,50 Two trials in-
cluded at least 97% of randomized patients in their survival
analyses,45,46 and one included all eligible patients but did not
report whether any randomized patients were considered
ineligible.49 Four trials reported the type of radiotherapy
equipment used (linear accelerators44,49; cobalt-6048–50). Six
trials included only patients with a good PS (Karnofsky
6044 or 70,48 ECOG/World Health Organization
0-246,47,49,50), and one required a weight loss of 10% within
the previous 6 months.49 One trial involved 7% of patients
with a World Health Organization PS of 3.45
Only one of the seven trials detected a statistically
significant survival difference between chemoradiation and
radiation alone.49 That small, single-center trial recruited only
51 of the planned 120 patients and was likely underpowered
to provide a reliable comparison of survival.49 Of the other
six trials, two used older treatment regimens that are not used
in Canada,44,45 including one trial that closed early because of
greater toxicity with the combined treatment45; the results of
one small trial should be considered with caution because
most of the 14% of patients excluded from the analyses were
from the chemoradiation treatment group,47 and one was a
phase II trial and was not designed to compare survival
among treatments.50 Three trials included in the meta-analy-
ses4,6,30 were subsequently updated and reported a statisti-
cally significant survival advantage for chemoradiation com-
pared with radiation alone.51–53
Chemoradiation was generally associated with increased
grade 3 or 4 toxicities compared with radiation alone, including
neutropenia (13% versus 0%,44 57% versus 14%,48 27% versus
7%50), anemia (80% versus 15%,48 27% versus 13%50), throm-
bocytopenia (6% versus 3%,44 37% versus 3%50), nausea and
vomiting (100% versus 0%,44 8% versus 3%,45 24% versus
0%,48 73% versus 17%50), esophagitis (12% versus 3%,45 76%
versus 28%48), and skin reactions (75% versus 30%48). Ulutin et
al.49 reported limited toxicity data, although chemoradiation was
associated with higher rates of grade 3 or greater pulmonary
toxicity (16% versus 0%).49
Only one trial assessed patient QOL using a validated
scale.46 In a subgroup of 67 patients completing an adaptation
of the EORTC questionnaire, the mean change in QOL scores
over 6 weeks favored chemoradiation (p  0.0002). How-
ever, these results were limited by the small number of
participating patients, the assignment of most patients to
chemoradiation (42 of 67 patients), and the fact that only 50
of the 67 patients completed questionnaires at both baseline
and 6 weeks.
Chemoradiation Versus Hyperfractionated or
Accelerated Radiation Alone
Hyperfractionation is defined as the use of two or more
fractions daily of smaller than conventional fraction size.
This results in an increased total nominal tumor dose com-
pared with standard radiation. The rationale is to exploit the
enhanced repair capacity of dose-limiting, late-reacting, nor-
mal tissues compared with rapidly proliferating tumors. Ac-
celerated radiation therapy is defined as the use of two or
more fractions of standard fraction size daily to the same
conventional total dose as standard radiotherapy but increas-
ing the number of fractions per week and shortening the
overall treatment time. The intent of accelerated radiation
therapy is to reduce repopulation in rapidly proliferating
tumors. Acute normal tissue toxicity is usually increased.
Four randomized trials compared a hyperfractionated or
accelerated radiotherapy regimen with a chemoradiation reg-
imen involving a similar radiotherapy schedule (Table
5).54–57 One of those trials55 was also included in the meta-
analysis by Pritchard et al.,30 and all were included in the
meta-analyses conducted by Rakovitch et al.31 and Rowell et
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al.32 Only the latter meta-analysis reported separate results for
hyperfractionated radiotherapy in an unplanned, exploratory,
subgroup analysis.
Two trials involved multiple clinical sites,56,57 and all
used linear accelerators to deliver radiotherapy. Two trials
involved central randomization stratified by PS, histology,
and clinical site.56,57 Three trials estimated the required sam-
ple size to detect a specified survival improvement,55–57 but
only one enrolled the stated number of required patients.57
With the exception of one trial that closed early,56 95% to
98% of randomized patients were included in the survival
analyses. All of the trials only included patients with a
moderate or good PS (Karnofsky 5054,55; ECOG 0-157;
ECOG 0-256), and two required that weight loss be less than
or equal to 10%.56,57
Two trials conducted by Jeremic et al.54,55 detected a
statistically significant survival advantage for concurrent che-
moradiation with hyperfractionated radiotherapy versus hy-
perfractionated radiotherapy alone. In one of the trials, the
survival benefit was specific to a chemotherapy regimen
using a lower dose of carboplatin, although both chemother-
apy treatment groups received equal doses of etoposide.54 In
the other trial, chemoradiation also resulted in a significant
benefit on local (median, 25 versus 20 months; p 0.015) but
TABLE 4. Randomized trials of conventional radiation with versus without chemotherapy (not included in the meta-analyses)
Study Disease stage Treatment n
Response
CR & PR (%)
Survival
Median
(mo)
Rate
(%)
Minet et al.44 I-IV
RT: 24 Gy, 6 fx, 2 wks x 2, with 2 wks rest
in between.
RTCT: RT as above  cyclophosphamide
400 mg/m2, vindesine 3 mg/m2,
doxorubicin 40 mg/m2,  cisplatin 40 mg/
m2 wks 1, 5, 13, then monthly x 8, 
vindesine 3 mg/m2 wks 2 & 6
40
41
NR
6.8
8.0
1 yr/2 yr
31/63
5/10
2  0.171, p  NS
Ball et al.45 NR,
advanced RT: 20 Gy, 5 fx,1 wk
RTCT: RT as above  concurrent
continuous infusion fluorouracil 1 g/m2
daily x 5
204 total
NR
NR
16 (95% CI, 9-24)
29 (95% CI, 21-39)
p  0.035
6.0a
6.8a
1 yr/2 yra
26/7
26/9
p  0.36
Cullen et al.46 NR,
localized
disease
RT: 40 Gy, 15 fx
CT-RT: Induction mitomycin
6 mg/m2, ifosfamide 3 g/m2, 
cisplatin 50 mg/m2, every 3 wks
x 4 then RT as above
461 total
NR
NR
45
53
p  0.12b
9.7
11.7
2 yr/3 yr
16/8
20/2
p  0.14 2
Kim et al.47 IIIA/B
RT: 60-65 Gy, 6-7 wks
CT-RT: Induction cisplatin 20 mg/m2
days 1-5, etoposide 100 mg/m2 days
2-4,  vinblastine 6 mg/m2 day 1, every
3 wks x 3 then RT as above
50
53
67
65
8.5
13.8
1 yr/2 yr
35/19
50/18
p  0.371 log rank
Sharma et al.48 IIIA/B
RT: 55-60 Gy, 5.5-6 wks
CT-RT: Induction cisplatin 50 mg/m2,
ifosfamide 2 g/m2,  mitomycin C 6
mg/m2 every 3 wks x 3 then RT as
above
506 total
NR
NR
42.2
62.3
NR
13.1
2 yr/3 yrc
7.4/5.2
20.1/11.5
Ulutin et al.49 IIIA/B RT: 56 Gy BEDd(split-course), 2.5-3 Gy/d
CTRT: RT as above  paclitaxel (3-hr
infusion) 60 mg/m2 day 1, 8, 15 & 23
NR
NR
70
92
p  0.003
12.0
15.2
NR
NR
p  0.027 log rank
Beslija et al.50 IIIA/B RT: 63 Gy, 34 fx
CT- RT: Induction cisplatin 80 mg/m2
day 1  gemcitabine 1250 mg/m2 days
1 & 8, every 3 wks x 3, then RT as above
30
30
26.6
46.6
p  0.324
10.0
12.5
1 yr
24
43
p  0.639 log rank
BED, biologically equivalent dose; CI, confidence interval; CR, complete response; CT, chemotherapy; fx, fraction(s); NR, not reported; NS, not statistically significant; PR, partial
response; RT, radiotherapy.
aEstimated survival rates.
bFor 370 assessable.
cThe survival data are actuarial at 2 years and projected for 3 years.
d Total radiotherapy dose was 48.5 Gy (3 Gy/d  12 given 5 days/wk then 2.5 Gy/day for days 3-7 of wk 4).
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not distant (p  0.33) recurrence-free survival.55 Of the two
trials that did not detect a treatment difference in survival, one
recruited only 110 of the target 375 patients and was underpow-
ered for a survival comparison,56 and one found that accelerated
radiotherapy, with or without chemotherapy, did not signifi-
cantly improve survival compared with standard radiotherapy,
with or without chemotherapy (p  0.76).57
Toxicity data were reported variably in the four trials.
In the earlier trial by Jeremic et al.,54 chemoradiation was
associated with higher rates of grade 4 acute toxicity (high-
dose carboplatin; p  0.039) and grade 3 or 4 late toxicity
(low-dose carboplatin, p 0.024; high-dose carboplatin, p
0.033). However, in the later trial by Jeremic et al.,55 there
were no statistically significant group differences on grade 3
or 4 acute (p  0.44) or late (p  0.75) toxicities. No
treatment-related deaths were reported in either of the trials
by Jeremic et al.54,55 Bonner et al.56 observed higher rates of
grade 3 or greater nausea and vomiting among patients
receiving chemoradiation (16% to 22% versus 3% to 6%),
and Ball et al.57 observed higher rates of grade 3 or 4
hematologic toxicities in patients given carboplatin (throm-
bocytopenia, 10% versus 0%; neutropenia, 15% versus 0%).
In that same trial, grade 3 or 4 esophagitis was also more
common with chemoradiation (34% versus 22%) and with
accelerated versus standard radiotherapy (32% to 48% versus
12% to 21%; p  0.0001), and four deaths were reported as
possibly related to the administration of accelerated radio-
therapy, with or without chemotherapy.57
Timing of Radiotherapy Relative to Chemotherapy
One meta-analysis and three randomized trials com-
pared concurrent chemoradiation with the sequential admin-
istration of chemotherapy and radiation,32,58–62 and three
trials (one reported in abstract report and slide presentation)
compared varying schedules of chemotherapy and radiother-
apy administration63–66 (Table 6).
All six randomized trials involved platinum-based che-
motherapy. Two trials were randomized phase II trials.61,66
All trials described how the required sample size was esti-
mated to detect a difference between treatments in the pri-
mary outcome of survival. Fewer than 3% of randomized
patients were excluded from the survival analyses in the four
reports providing those data.58,59,64,65 All trials included only
patients with a good PS (ECOG 0-164,65; ECOG 0-258,61;
Karnofsky 7059,66), and three limited enrollment to patients
with minimal weight loss (5%59 or 10%65,66).
Three randomized trials comparing concurrent with
sequential chemoradiation, including one reported in abstract
form, detected a statistically significant survival benefit for
concurrent treatment (median, 16.5 versus 13.3 months, p 
TABLE 5. Randomized trials of hyperfractionated or accelerated radiation with and without chemotherapy
Study
Disease
stage Treatment n
Response,
CR & PR
(%)
Survival
Median (mo) Rate (%) Overall
Jeremic et al.54 IIIA/B
HFX RT: 64.8 Gy, 1.2 Gy BID
HFX RTCT: RT as above  concurrent
carboplatin 100 mg days 1 and 2 and
etoposide 100 mg days 1-3, given wkly
during RT
HFX RTCT: RT as above  concurrent
carboplatin 200 mg days 1 and 2, and
etoposide 100 mg days 1-5, wks 1, 3, and 5
61
58
59
62
74
62
p  NS
8
18
13
2 yr/5 yr
25/5
35/21
27/16
RT vs. low-dose
carboplatin
p0.0027 log rank
RT vs.
high-dose
carboplatin,
p0.17 log rank
Low-dose vs. high-
dose carboplatin,
p0.14 log rank
Jeremic et al.55 IIIA/B
HFX RT: 69.6 Gy, 1.2 Gy BID
HFX RTCT: RT as above  concurrent
carboplatin 50 mg and etoposide 50 mg
daily
68
67
84
92
p  0.18
14
22
2 yr/4 yr
26/9
43/23
p0.021
log rank
Bonner, et al.56 IIIA/B RT: 60Gy, 30 daily fx, 6wks
HFX RTCT: 30Gy, 1.5Gy BID x 2 (split-
course)  concurrent cisplatin 30 mg/m2
and etoposide 100 mg/m2, both days 1-3
and 28-30.
HFX RT: RT as above
110 total 21
25
45
8.6
11.6 for all
BID patients
NR Daily vs. BID RT
comparison,
p0.10 log rank
Ball et al.57 I-III
RT: 60 Gy, 30 fx, 6 wks
RTCT: RT as above  concurrent
carboplatin 70 mg/m2/day x 5, wks 1 and 4
Acc RT: 60 Gy, 30 fx, 3 wks
Acc RTCT: RT as above  concurrent
carboplatin
70 mg/m2/day x 5, wk 1
53
56
48
51
53
61
61
59
p  0.82
Estimated
NR
20.3
NR
NR
Estimated
2 yr
26
41
33
24
p0.43 log rank
Acc, accelerated; BID, twice daily; CR, complete response; CT, chemotherapy; fx, fraction(s); HFX, hyperfractionated; NR, not reported; NS, not statistically significant; PR,
partial response; RT, radiotherapy.
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0.04; 17.0 versus 14.6 months, p  0.046; 16.6 versus 12.9
months, p  0.023) after a median follow-up of 5 years,58 6
years,59 and 39 months.61 In one of those trials, the survival
advantage was specific to concurrent treatment with daily
radiotherapy but not twice-daily radiotherapy.59 Radiation
therapy was primarily delivered by linear accelerator in one
trial58 and Cobalt-60 machines in another.61 In the trial by
Furuse et al.,58 delivery of protocol-defined treatment was
comparable for both concurrent and sequential schedules
(82% to 83% of patients); however, post-protocol chemother-
apy was administered to more patients after concurrent che-
moradiation (59% versus 25%). In the randomized phase II
trial by Zatloukal et al.,61 which was terminated early because
of slow accrual and a statistically significant unplanned in-
terim analysis, fewer patients in the sequential group received
the protocol-defined treatment compared with the concurrent
group (four cycles of chemotherapy, 58% versus 83%; any
radiotherapy, 64% versus 94%, p  0.0002). Reasons for
these treatment imbalances are unclear, although they may be
related to treatment effectiveness, with higher rates of che-
motherapy discontinuation because of disease progression
among patients receiving sequential chemoradiation (20%
TABLE 6. Randomized trials of radiotherapy timing relative to chemotherapy
Study
Disease
stage Treatment n
Response,
CR & PR (%)
Survival
Median (mo) Rate (%)
Furuse et al.58 IIIA/B
CT-RT: vindesine 3 mg/m2 days 1, 8, 29, 36, cisplatin
80 mg/m2 days 1, 29, and mitomycin 8 mg/m2 days 1,
29, then RT, 56 Gy, 28 fx, 5 wks
CTRT: CT as above  concurrent RT, 56 Gy, 28 fx,
3 wks x 2 (split-course)
320 total
NR
NR
66
84
p  0.0002
13.3
16.5
p  0.04 log rank
1 yr/5 yr
55/9
64/16
Curran et al.59,60 II-III
CT-RT: Cisplatin 100 mg/m2 days 1, 29, and
vinblastine 5 mg/m2 wkly x 5, then RT, 63 Gy total
CTRT: CT as above concurrent with daily RT as
above
CTHFX RT: Cisplatin 50 mg/m2 days 1, 8, 29, 36,
and oral etoposide 50 mg/m2 BID x 10, weeks 1, 2, 5,
6, concurrent with RT BID, 69.6 Gy total
610 total
59
68
63
14.6
17.0
15.2
2 yr/4 yr
31/12
37/21
32/17
CT3RT vs. CTRT, p  0.046;
CT3RT vs. CTHFXRT,
p  0.296
Vokes et al.63,64 III
RTCT: RT 66 Gy with concurrent paclitaxel 50 mg/
m2 and carboplatin AUC 2 given wkly
CT-CTRT: Paclitaxel 200 mg/m2 and carboplatin
AUC 6 q3wks x 2 followed by concurrent CT and RT
as above
182
184
66
61
11.4
13.7
2 yr/3 yra
28/18
32/24
HR 0.85, p  0.138
Zatloukal et al.61 IIIA/B
CT-RT: Cisplatin 80 mg/m2 day 1 and vinorelbine,
12.5 mg/m2 (cycles 2 & 3), 25 mg/m2 (cycles 1 & 4),
days 1, 8, 15, q4wks, then RT, 60Gy, 30fx, 6wks
CTRT: CT as above  concurrent RT as above,
starting day 4 of CT cycle 2
50
52
98 evaluable
47
80
p  0.001
12.9
16.6
1 yr/2 yr/3 yr
53/14/10
69/34/19
HR 0.61, 95% CI, 0.39-0.93;
p  0.023 log rank
Fournel et al.65 IIIA-N2/B
CT-RT: Cisplatin 120 mg/m2 days 1, 29, 57 and
vinorelbine 30 mg/m2/wk from day 1 - 78, then RT,
66 Gy, 33 fx, 6.5 wks
CTRT-CT: Cisplatin 20 mg/m2 and etoposide 50
mg/m2, both days 1-5 and 29-33, concurrent with RT
as above, then cisplatin 80 mg/m2 days 78, 106, and
vinorelbine 30 mg/m2/wk from days 78 - 127
101
100
41b
32b
p  0.56
14.5
16.3
p  0.24 log rank
2 yr /3 yr/4 yr
26/19/14
39/25/21
Belani et al.66 IIIA/B
CT-RT: Paclitaxel 200 mg/m2 and carboplatin AUC 6,
q3wks x 2, then RT, 63 Gy, 34 fx, 7 wks
CT-RTCT: CT as above, then RT with concurrent
paclitaxel 45 mg/m2 and carboplatin AUC 2 mg/mL
q3wks x 2
CTRT-CT: Concurrent CT and RT as above, then
paclitaxel 200 mg/m2 and carboplatin AUC 6 mg/mL
q3wks x 2
91
74
92
NR
NR
NR
13.0
12.7
16.3
1 yr/2 yr/3 yr
57/30/ 17
53/25/15
63/31/17
AUC, area under the curve; BID, twice daily; CI, confidence interval; CR, complete response; CT, chemotherapy; fx, fraction(s); HFX, hyperfractionated; HR, hazard ratio; NR,
not reported; PR, partial response; RT, radiotherapy. a Estimated. b Intent-to-treat analysis.
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versus 10%). Sequential treatment was also associated with
higher rates of chemotherapy discontinuation because of
toxicity or other unspecified reasons (20% versus 6%), even
though grade 3 or 4 toxicity was more common with concur-
rent treatment. The reasons for the significant differences in
the amount of radiotherapy administered are unclear.
Limited toxicity data were reported in two of the three
trials, although toxicities were generally more frequent with
concurrent chemoradiation. Furuse et al.58 reported more
frequent myelosuppression with concurrent treatment (p 
0.0001) and identical rates of esophageal toxicity for concur-
rent and sequential chemoradiation. Curran et al.59 observed
higher rates of acute grade 3 or 4 esophagitis with concurrent
treatment (4% sequential, 25% concurrent with standard
radiotherapy, and 47% concurrent with hyperfractionated
radiotherapy), and hyperfractionated concurrent radiation
was associated with less frequent grade 4 or 5 neutropenia
than standard sequential or concurrent chemoradiation (48%
versus 56% to 58%). Late toxicities in the latter trial were
similar for concurrent and sequential chemoradiation. With
the exception of renal or hepatic toxicity (2% in each treat-
ment group), all grade 3 or 4 toxicities reported by Zatloukal
et al.61 were more frequent with concurrent chemoradiation,
including leukopenia (53% versus 19%, p  0.009), neutro-
penia (65% versus 40%, p  0.057), nausea and vomiting
(39% versus 15%, p  0.044), esophagitis (18% versus 4%,
p  0.076), and febrile neutropenia (8% versus 2%, not
statistically significant).
Three trials compared different chemoradiation sched-
ules. Fournel et al.65 compared sequential chemoradiation
with concurrent chemoradiation followed by consolidation
chemotherapy, using the same total dose of cisplatin in each
treatment arm. In a randomized phase II trial conducted by
Belani et al.,66 patients were randomized to sequential che-
motherapy followed by radiation, induction chemotherapy
followed by concurrent chemoradiation, or concurrent che-
moradiation followed by consolidation chemotherapy, using
the same chemotherapy and radiotherapy doses in the latter
two treatment arms. After interim analysis, the arm receiving
induction chemotherapy followed by concurrent chemoradia-
tion was closed to patient accrual because of a low likelihood
of survival benefit when compared with a historical control of
sequential chemoradiotherapy. Vokes et al.63,64 used a similar
regimen to that of Belani et al.66 for induction chemotherapy
followed by concurrent chemoradiation and compared that
with immediate concurrent chemoradiation. None of these
trials reported a statistically significant survival advantage for
any treatment schedule. Concurrent chemoradiation was gen-
erally found to be more toxic than sequential treatment, and
Vokes et al. reported that grade 4 events were more frequent
when induction chemotherapy was added to concurrent che-
moradiation.
Rowell and O’Rourke32 pooled the 2-year survival data
from three trial abstracts comparing concurrent with sequen-
tial chemoradiation. Two of these trials have been published
in full, and all three trials are included in Table 6.59,61,65 The
authors excluded the trial by Furuse et al. from their analysis
because the radiotherapy administration schedule differed
between the two treatment arms,58 and they included the trial
by Fournel et al.65 The latter trial, which was described as a
comparison of sequential versus concurrent chemoradiation,
included the same total dose of cisplatin in each treatment
arm; however, two cycles of chemotherapy were adminis-
tered after the completion of concurrent chemoradiation.
Given the inclusion of the trial by Fournel et al., it is unclear
why the ACR 427 trial66 published at that time in abstract
form67,68 was not considered for the meta-analysis. The re-
sults of the meta-analysis showed a significant survival ben-
efit for concurrent versus sequential chemoradiation at 2
years (RR, 0.86; 95% CI, 0.78-0.95; p  0.003); however,
acute esophagitis (grade 3) was also more frequent with
concurrent chemoradiation (17% to 26% versus 0% to 4%;
p  0.00001). The authors commented on the limitations of
pooling data from abstract trial reports and suggested that,
although concurrent chemoradiation was associated with a
survival benefit in the meta-analysis, sequential chemoradia-
tion should still be considered the standard of care until
longer-term survival data are available and more detailed
toxicity information is reported. Two of the trials in the
meta-analysis have now been published in full,65,69 providing
more detailed toxicity data, and another fully published trial
that was excluded from the meta-analysis provides relevant
and detailed outcome data.58
Trials Comparing Different Chemotherapies
within Chemoradiation Regimens
Eight randomized trials have compared different che-
motherapy regimens within a combined-modality treatment
approach, including two reported in abstract form (Table
7).70–77 Three older trials involved treatment approaches that
are no longer used in Canada (split-course radiotherapy in
combination with chemotherapy regimens involving
lonidamine,71 DTIC,70 or cyclophosphamide with doxorubi-
cin70,72) and are summarized in Table 7 but are not discussed
in further detail. Similarly, data from two abstract reports of
small trials are presented in Table 7 but are not discussed in
the text. Although both reports provide an indication of
activity for the chemotherapy regimens used, the trials were
not designed76 or powered74 to compare survival among
treatments.
Of the remaining three trials, two were randomized
phase II trials.73,77 Two trials reported using linear accelera-
tors to deliver radiotherapy,75,77 although Vokes et al.77 also
used Cobalt-60 machines. One of the randomized trials re-
ported using a centralized randomization process,77 and two
trials met projected sample size requirements.75,77 Between
93%73 and 98%75 of randomized patients were included in the
trial survival analyses, with exclusion primarily the result of
patient ineligibility or failure to receive trial treatment. In two
of the trials, enrollment was limited to patients with a good
PS (0-1) and limited weight loss (5% in the 3 to 6 months
pre-diagnosis).73,77
Vokes et al.75 detected no statistically significant dif-
ferences in objective response, overall survival, or local
progression-free survival (2 years, 44% versus 37%; 5 years,
27% versus 28%; p  0.66) for concurrent chemoradiation
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TABLE 7. Randomized trials of chemoradiation comparing different chemotherapy regimens
Study Disease stage Treatment n
Response,
CR & PR (%)
Survival
Median (mo) Rate (%)
Eagan et al.70 NR
Locally
advanced
Both treatment arms: Cyclophosphamide 400 mg/
m2 and doxorubicin 40 mg/m2 q4wks x 10 plus
concurrent split-course RT, 20 Gy, 5 fx over
5-7 days, wks 1 and 5.
Arm 1: Cisplatin 40 mg/m2 q4wks x 10
Arm 2: DTIC 200 mg/m2 days 1-3 q4wks x 10
37
35
59
47
pNS
16.
67.1
p  0.01
NR
Gallo-Curcio et al.71 I–III
Arm 1: CT, cisplatin 100 mg/m2 day 1 
etoposide 120 mg/m2 days 4, 6, 8, q4wks x 2,
followed by 3wk split-course RT, 30 Gy  20
Gy, and 2 additional cycles of CT
Arm 2: As arm 1  lonidamine 150 mg orally
3 daily until tumor progression
56
60
17
19.5
Actuarial
10.3
9.9
p 0.44
Actuarial 2 yr
11
30
p  0.34
Robinow et al.72 II-III All treatment arms: Cyclophosphamide 400 mg/
m2 day 3, doxorubicin 40 mg/m2 day 1, and
cisplatin 20 mg/m2 days 1-3 (reduced to 8 mg/
m2 days 1-5 during RT) x 5 cycles plus
concurrent split-course RT, 20 Gy, 4 Gy/fx,
cycles 3 & 4
Arm 1: No additional CT
Arm 2: Etoposide 60 mg/m2 days 1-3
Arm 3: Triazinate 150 mg/m2 (reduced to 125
mg/m2 during RT) days 1-3
48
47
31
NR
NR
NR
14.8
16.2
14.6
1 yr/3 yr/5 yr
61/13/3
67/26/18
56/20/16
Arm 1 vs. Arm 2 p  0.08
Clamon et al.73 IIIA/B Both treatment arms: Cisplatin 100 mg/m2 days 1,
29 and vinblastine 5 mg/m2 days 1, 8, 15, 22, 29
followed on day 50 by RT, 60 Gy, 30 fx, 6 wks
Arm 1: Cisplatin 100 mg/m2 q4wks x 4, and
vinblastine 5 mg/m2 q2wks x 8, starting 3 wks
post-RT
Arm 2: Carboplatin 100 mg/m2 wkly x 6, given
concurrently with RT
91 total
NR
NR
53 (95% CI,
34-75)
59 (95% CI,
43-74)
11.9
12.44
NR
Morales et al.74 IIIA/B Both treatment arms: cisplatin-based CT q3wks x
3, followed after 4 wks by RT, 60 Gy over
6 wks
Arm 1: No additional CT
Arm 2: Paclitaxel 60 mg/m2 wkly x 6, given
concurrently with RT
35 total
NR
NR
54
73
10
13
NR
NR
Jeremic et al.75 IIIA/B
Arm 1: HFX RT, 69.6 Gy, 1.2 Gy BID weekdays
 concurrent carboplatin and etoposide, both
50 mg daily on weekdays
Arm 2: HFX RT as above  concurrent
carboplatin and etoposide, both 30 mg daily on
weekdays and 100 mg daily on weekends
101
99
85
88
p  0.68
20
22
p  0.57 log rank
1 yr/3 yr/5 yr
80 /29/20
78/34/ 23
Vokes et al.77 IIIA/B All treatment arms: CT given q3wks x 4 
concurrent RT 66 Gy, 2 Gy/fx, cycles 3 & 4
Arm 1: CT, cisplatin 80 mg/m2 day 1 
gemcitabine 1250 mg/m2 cycles 1 & 2, 600
mg/m2 cycles 3 & 4, days 1,8
Arm 2: CT, cisplatin 80 mg/m2 day 1 
paclitaxel 225 mg/m2 cycles 1 & 2, 135 mg/m2
cycles 3 & 4, day 1
Arm 3: CT, cisplatin 80 mg/m2 day 1 
vinorelbine 25 mg/m2 cycle 1 q1wk, cycle 2
days 1,8; 15 mg/m2 cycles 3 & 4, days 1,8
187
total
NR
NR
NR
74
(95% CI, 60-86)
67
(95% CI, 52-80)
73
(95% CI, 57-85)
18.3
(95% CI, 13.8-23.6)
14.8
(95% CI, 12-19.5)
17.7
(95% CI, 12.4-24.7)
1 yr/3 yr
68/28
62/19
65/23
Antonadou et al.76 IIIA/B Both treatment arms: RT 55-60 Gy, 2 Gy/fx, 5-6 wks
Arm 1: Concurrent weekly paclitaxel 60 mg/m2
Arm 2: Concurrent weekly carboplatin AUC 2
85 total
NR
NR
89
80
p  0.043
NR 6 mo
83
71
p  0.267
AUC, area under curve; BID, twice daily; CI, confidence interval; CR, complete response; CT, chemotherapy; DTIC, dacarbazine; fx, fraction(s); HFX, hyperfractionated; NR,
not reported; NS, not statistically significant; PR, partial response; RT, radiotherapy.
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involving hyperfractionated radiotherapy, with or without che-
motherapy administered on the weekend, respectively. That trial
was imbalanced in the proportion of patients with stage IIIA
disease receiving each chemotherapy regimen (gemcitabine-
cisplatin, 63%; paclitaxel-cisplatin, 52%; vinorelbine-cisplatin,
40%), which could have had an impact on trial outcomes.77
Toxicity varied in each trial according to the chemo-
therapy regimen used. Clamon et al.73 observed generally
comparable or more frequent grade 3 or 4 toxicity with
sequential cisplatin-vinblastine compared with concurrent
carboplatin (granulocytopenia, 53% versus 17%, p  0.003;
leukopenia, 43% versus 19%; peripheral neuropathy, 17%
versus 0%, p  0.007; nausea/vomiting, 20% versus 7%,
p  0.175). However, thrombocytopenia was more common
in the carboplatin treatment arm (12% versus 0% of patients,
p  0.058).73 Jeremic et al.75 reported comparable toxicity
data for regimens with or without weekend chemotherapy,
with the exception of grade 3 or 4 hematologic toxicity (29%
versus 12%, p  0.0046) and treatment interruptions (21%
versus 6%, p  0.0018), which were more common with
weekend treatment. During the induction chemotherapy
phase of the trial by Vokes et al., grade 3 or 4 granulocyto-
penia was common in all treatment arms (48% to 55%), grade
3 or 4 thrombocytopenia occurred more frequently with
gemcitabine-cisplatin (25% versus 0% to 2%), grade 3 or 4
leukopenia was more common with vinorelbine-cisplatin
(27% versus 12% to 15%), and two treatment-related deaths
occurred in the paclitaxel-cisplatin treatment arm.77 During
concurrent chemoradiation, grade 3 or 4 toxicity was gener-
ally more frequent with gemcitabine-cisplatin compared with
paclitaxel-cisplatin or vinorelbine-cisplatin, respectively:
thrombocytopenia (56% versus 6% versus 2%), anemia (32%
versus 4% versus 19%), granulocytopenia (51% versus 53%
versus 27%), and esophagitis (52% versus 39% versus 25%).
Radiotherapy interruptions were also more common with
gemcitabine-cisplatin (35% versus 13% to 16%). However,
one death resulting from treatment-related respiratory failure
was associated with vinorelbine-cisplatin chemoradiation.
DISCUSSION
To date, the evidence is insufficient to determine the
most appropriate dose, schedule, or timing of radiotherapy in
the palliation of locally advanced NSCLC. There is only one
fully published trial comparing immediate with delayed ad-
ministration of radiotherapy, and it did not detect any differ-
ence in symptom control or survival, although the trial was
likely underpowered to detect a survival difference.23 There
are no consistent data to suggest the superiority of one
radiotherapy schedule versus another, but among the trials
comparing different doses and schedules of radiotherapy for
the palliation of symptoms, the most commonly reported
schedule was 17 Gy given in two fractions over 1 week. That
radiation dose and fractionation schedule is used primarily in
the United Kingdom. A Medical Research Council trial
involving more than 500 patients detected a statistically
significant survival advantage for a schedule of 39 Gy given
in 13 fractions over 3 weeks compared with the 17 Gy
schedule; however, that study was limited to patients with
good PS. The survival advantage was offset, in part, by lower
levels of symptom palliation for the 39 Gy schedule.24 Bezjak
et al.19 randomized 230 patients to the commonly used
Canadian schedule of 20 Gy in five fractions and compared
this with a hypofractionated schedule of 10 Gy given in a
single fraction. Although that trial detected no significant
difference in the primary outcome of symptom control, a
statistically significant advantage for the multi-fractionated
schedule was observed on the secondary outcomes of survival
and QOL. Another trial reported in abstract form observed
significantly better symptom palliation with a multi-fraction-
ated schedule compared with a single fraction of 10 Gy.15
Based on this evidence, reasonable schedules of radiotherapy
for symptom palliation for symptomatic patients with poor PS
and significant weight loss include 20 Gy in five fractions and
17 Gy in two fractions administered 1 week apart. Shorter
regimens, including single fractions of less than 10 Gy,
should not be considered a standard approach but may be
appropriate in some clinical circumstances.
With regard to curative treatment, one large individual
patient data meta-analysis and five smaller overlapping meta-
analyses all demonstrate a statistically significant survival ad-
vantage for chemoradiation therapy, particularly platinum-
based, compared with radiotherapy alone.4,6,29–33 The absolute
improvement in survival is small and in the order of 4% at 2
years and 2% at 5 years.4,29 This magnitude of survival benefit,
however, is generally considered to be clinically significant. This
small difference in absolute survival benefit may explain why
individual clinical trials have frequently failed to detect a sig-
nificant survival advantage for this treatment approach.
One meta-analysis and all three trials that compared
sequential with concurrent chemoradiation detected a statis-
tically significant survival benefit for concurrent administra-
tion.32,58,59,61 Only limited toxicity data have been reported,
and hematologic58,61 and non-hematologic32,59,61 toxicities
were more frequently associated with concurrent chemora-
diation. Based on this evidence, concurrent chemoradiation is
recommended for patients with good PS and minimal weight
loss. A reasonable treatment schedule includes cisplatin-
based chemotherapy and thoracic radiation of at least 60 Gy
in 30 fractions given over a 6-week period. When concurrent
chemoradiation is used, the two treatment modalities should
be started at the same time and as early as possible after
diagnosis. The patient and physician should have a full
discussion of the benefits, limitations, and toxicities of ther-
apy, and if the toxicities are felt to be unacceptable by the
patient, sequential chemoradiation may be an alternative
treatment option recognizing that survival benefits are infe-
rior to concurrent therapy.
The role of induction or consolidation chemotherapy in
combination with concurrent chemoradiation is unclear. One
noncomparative trial observed a trend toward a survival
benefit for immediate concurrent chemoradiation, followed
by consolidation chemotherapy compared with induction che-
motherapy, followed by concurrent chemoradiation.66 The
other trial detected no statistical difference in survival for
chemoradiation with or without induction chemotherapy.63,64
A recent phase II trial using consolidation docetaxel after con-
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current chemoradiation in patients with stage IIIB disease has
shown promising results78; however, that will need to be con-
firmed by randomized trials. If clinicians choose to administer
consolidation chemotherapy in line with recent randomized
trials, two or three cycles could be administered.65–68,78
Evidence in favor of using chemotherapy as a radio-
sensitizer is limited and inconsistent. Local control may be
improved when cisplatin is administered in divided doses
either daily or less frequently but concurrent with radiother-
apy. Two of the seven trials using cisplatin as a radiosensi-
tizer with concurrent radiotherapy demonstrated a statistically
significant survival advantage at 3 years.38,41 That observation
lends some further support to the results of the studies evaluating
concurrent versus sequential chemoradiation. The evidence for
using altered fractionation radiotherapy within a chemoradiation
regimen is limited and suggests that the use of hyperfractionated
radiotherapy should be confined to clinical trials.
The impact of chemoradiation on QOL or symptom
control is uncertain because none of the meta-analyses eval-
uated these outcomes and, of the two chemoradiation trials
that formally assessed QOL, one only enrolled 67 of 461
patients in the QOL assessment,46 and the other did not detect
any statistically significant differences on the EORTC QOL
scales.42 Patients receiving chemoradiation generally experi-
ence higher rates of toxicity than those given radiotherapy
alone. In individual clinical trials, serious hematologic ad-
verse effects occurred more frequently when carboplatin was
given concurrently with radiotherapy,40,42 severe nausea and
vomiting occurred more often when cisplatin-based chemother-
apy was given concurrently38,44,56 or sequentially48 with radia-
tion, and esophagitis was worse with both carboplatin-based42,57
and cisplatin-based39,48 chemoradiation. The results of two
meta-analyses also indicated that neutropenia31 and esophagitis
(grade 3)31,32 are more common with chemoradiation.
Although the evidence supports combining cisplatin-
based chemotherapy with radiotherapy to improve survival,
particularly when the two are administered concurrently,
there are insufficient data to determine which chemotherapy
regimen or radiotherapy schedule is most effective. Cisplatin
combined with etoposide,78–80 vinorelbine,61,77 or vinblas-
tine59,60 has yielded reasonable survival in clinical trials.
Full-dose vinorelbine (25-30 mg/m2 weekly) should not be
used in combination with cisplatin and concurrent radiother-
apy because of toxicity concerns. In a phase I dose-escalation
trial, higher rates of severe myelosuppression and esophagitis
were observed with standard doses of vinorelbine (20-
25mg/m2 weekly) and cisplatin (100mg/m2 every 3 weeks)
compared with lower doses of each agent (vinorelbine 15
mg/m2 days 1 and 8, and cisplatin 80 mg/m2 day 1 every 3
weeks) combined with concurrent radiotherapy.81 The two
trials of concurrent cisplatin-vinorelbine and radiotherapy in
this review used a lower dose of vinorelbine (12.5-15 mg/m2
generally administered weekly).61,77
Adequate assessment of PS is important when evaluat-
ing treatment options for patients with unresected NSCLC.
For patients with a good PS and minimal weight loss, there is
a definite survival benefit for chemoradiation with cisplatin-
based regimens compared with radiotherapy alone. As most
of the chemoradiation trials reviewed in this systematic re-
view involved patients with a good PS (generally ECOG/
World Health Organization2 or Karnofsky70), and some
required patients to have limited weight loss (5% to 10%);
recommendations for a curative treatment approach should be
limited to that patient group. Concurrent chemoradiation with
cisplatin-based chemotherapy and thoracic radiation of at
least 60 Gy in 30 fractions given over a 6-week period is a
reasonable regimen. Cisplatin combined with etoposide, vi-
norelbine, or vinblastine have achieved reasonable survival
and are acceptable treatment combinations. There is limited
evidence for patients with good PS who refuse combined
modality treatment. One randomized trial found a survival
benefit for a radiation regimen using 39 Gy in 13 fractions
compared with 17 Gy in two fractions for patients with good
PS.24 Radiation alone with 39 Gy in 13 factions may be an
alternative, although this fractionation scheme is not gener-
ally used in Canada. There is no consensus among radiation
oncologists on a standard radiotherapy regimen for this pop-
ulation in Canada. Depending on the goals of therapy, clini-
cians may offer these patients radical or palliative radiother-
apy alone. For less fit patients for whom potential toxicity
may be a concern, sequential therapy is a treatment option,
depending on other patient factors and after a full discussion
with the patient of the treatment options, goals of therapy, and
potential adverse effects. For symptomatic patients with poor
PS and significant weight loss, palliative radiotherapy offers
the potential for symptomatic relief. Reasonable treatment op-
tions include 20 Gy in five fractions and 17 Gy in two fractions
administered 1 week apart. Hyperfractionated radiation is not
recommended outside the context of a clinical trial.
This review is limited by the lack of high-quality
evidence to recommend for or against the use of induction or
consolidation chemotherapy and to recommend specific che-
motherapy doses and schedules. Randomized controlled trials
addressing these questions should be the focus of future
clinical research.
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